The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 701–800 of 1,029
Yunn, N.-O., Koh, A., 한승민, Lim, J. H., Park, S., Lee, J., Kim, E., Jang, S. K., Berggren, P., & Ryu, S. H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv767 · Cited by 74
“Second, the development of receptor modulators is a valuable tool for drug discovery because membrane proteins account for ∼60% of all approved drug targets (7,8).”
BackgroundGanguly, S., Pucadyil, T. J., & Chattopadhyay, A. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.125732 · Cited by 82
“As a consequence, GPCRs represent major targets for the development of novel drug candidates in all clinical areas (7).”
BackgroundMassively Parallel Sequencing and Analysis of the Necator americanus Transcriptome
Cantacessi, C., Mitreva, M., Jex, A. R., Young, N. D., Campbell, B. E., Hall, R. S., Doyle, M., Ralph, S. A., Rabelo, É. M. L., Ranganathan, S., et al. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000684 · Cited by 73
“americanus contigs as drug targets ( = ‘‘druggability’’), the InterPro domains inferred from the predicted proteins were compared with those linked to known small molecular drugs which follow the ‘Lipinsky rule of 5’ regarding bioavailability [46,47].”
MethodA Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein
Pop, M. S., Stransky, N., Garvie, C. W., Theurillat, J.-P., Hartman, E. C., Lewis, T. A., Zhong, C., Culyba, E. K., Lin, F., Daniels, D. S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0689 · Cited by 65
“As an additional control to rule out nonspecific compound effects, we tested a small set of commercially available BRD32048 analogs that contain the [1,3,5]triazine core but vary either the methoxyphenyl group in the 4-position or the alkyl piperidine group in the 6-position.”
Boland, M. R., & Tatonetti, N. P. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.48 · Cited by 74
“Drugs with IC-50 values less than 10,000nM or 10 uM are considered potentially pharmacologically relevant inhibitors 66, 67 .”
Improved Computation of Protein–Protein Relative Binding Energies with the Nwat-MMGBSA Method
Maffucci, I., & Contini, A. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00196 · Cited by 74
Approaches to target tractability assessment – a practical perspective
Brown, K. K., Hann, M. M., Lakdawala, A. S., Santos, R., Thomas, P. J., & Todd, K. (2018) · MedChemComm · doi:10.1039/c7md00633k · Cited by 69
“…score ≥0.7 Bucket 5 (DrugEBIlity) Targets with 0 Ensembl score 0.7 Bucket 7 (ChEMBL) Targets with ligands (PFI ≤7, SMART hits ≤2, scaffolds ≥2) Bucket 8 (Hopkins & Groom 2002) Targets with a predicted ‘Ro5 druggable’ domain Bucket 9 (SureChEMBL) Targets with ‘chemical’ patents in the last 5…”
BackgroundInfluentialSmall Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Xu, K., Park, D., Magis, A. T., Zhang, J., Zhou, W., Sica, G., Ramalingam, S. S., Curran, W. J., & Deng, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1012-4 · Cited by 75
Inhibitoren der Proteintyrosinphosphatasen: Kandidaten für zukünftige Wirkstoffe?
Bialy, L., & Waldmann, H. (2005) · Angewandte Chemie · doi:10.1002/ange.200461517 · Cited by 70
Lipid–protein interactions, regulation and dysfunction of brain cholesterol
Chattopadhyay, A., & Paila, Y. D. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.032 · Cited by 76
“As a consequence, GPCRs represent major targets for the development of novel drug candidates in all clinical areas [34].”
BackgroundLi, P., Chen, J., Wang, J., Zhou, W., Wang, X., Li, B., Tao, W., Wang, W., Wang, Y., & Yang, L. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.07.001 · Cited by 70
Demir, Y., Türkeş, C., & Beydemir, Ş. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200218110645 · Cited by 68
Woolums, B. M., McCray, B. A., Sung, H., Tabuchi, M., Sullivan, J. M., Takle, K. A., Yang, Y., Mamah, C., Aisenberg, W. H., Saavedra-Rivera, P. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16411-5 · Cited by 73
Mass spectrometry-based biochemical assays for enzyme-inhibitor screening
de Boer, A. R., Lingeman, H., Niessen, W. M. A., & Irth, H. (2007) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2007.08.004 · Cited by 68
From Drug Target to Leads-Sketching A Physicochemical Pathway for Lead Molecule Design In Silico
Shaikh, S. A., Jain, T., Sandhu, G., Latha, N., & Jayaram, B. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782794220 · Cited by 84
“Knowledge of target characteristics, such as protein / nucleic acid sequence features, structural properties, proteomic profiles, pathway affiliation and roles, and tissue-distribution patterns, is useful for a molecular dissection of the mechanism of action of drugs and for predicting features to guide target discove…”
BackgroundBinding site elucidation and structure guided design of macrocyclic IL-17A antagonists
Liu, S., Dakin, L. A., Li, X., Withka, J. M., Sahasrabudhe, P. V., Li, W., Banker, M. E., Balbo, P., Shanker, S., Chrunyk, B. A., et al. (2016) · Scientific Reports · doi:10.1038/srep30859 · Cited by 69
Advances of droplet-based microfluidics in drug discovery
Wang, Y., Chen, Z., Bian, F., Shang, L., Zhu, K., & Zhao, Y. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1758663 · Cited by 70
Biological Relevance and Therapeutic Potential of the Hypusine Modification System
Pällmann, N., Braig, M., Sievert, H., Preukschas, M., Hermans‐Borgmeyer, I., Schweizer, M., Nagel, C., Neumann, M., Wild, P. J., Haralambieva, E., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664490 · Cited by 71
“Together, a growing body of research now indicates that the enzymes of the hypusine system fulfill certain criteria for being a potential therapeutic target (25, 26), and consequently, lead substances have been developed (27, 28).”
BackgroundFichter, K. M., Flajolet, M., Greengard, P., & Vu, T. Q. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013763107 · Cited by 73
“GPCRs are the largest family of cell-surface receptors and a major therapeutic target (9).”
BackgroundYagishita, N., Aratani, S., Leach, C. A., Amano, T., Yamano, Y., Nakatani, K., Nishioka, K., & Nakajima, T. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1129 · Cited by 68
“We have also demonstrated that this protein plays crucial roles in the pathological processes of RA (6), and could therefore be a candidate novel therapeutic target of RA (32).”
Alignment of Helical Membrane Protein Sequences Using AlignMe
Stamm, M., Staritzbichler, R., Khafizov, K., & Forrest, L. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057731 · Cited by 68
“Integral membrane proteins constitute 25–30% of the genes in a given genome [1–3] and play crucial roles in cell biology by allowing cells to interact with their environment; accordingly they constitute pharmacological targets for around 50% of active drugs on the market [4,5].”
BackgroundSouthan, C., Várkonyi, P., & Muresan, S. (2009) · Journal of Cheminformatics · doi:10.1186/1758-2946-1-10 · Cited by 65
“Last but not least, was the presci-ent estimate that the human genome could include 600– 1,500 tractable and therapeutically effective targets [35].”
BackgroundSabbadin, D., Ciancetta, A., & Moro, S. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400532b · Cited by 67
Chu, X., Shen, M., Xie, F., Miao, X.-J., Shou, W., Liu, L., Yang, P., Bai, Y.-N., Zhang, K., Yang, L., et al. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-101595 · Cited by 71
Singh, P., Paila, Y. D., & Chattopadhyay, A. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.135 · Cited by 67
“GPCRs represent major targets for the development of novel drug candidates in all clinical areas [2].”
BackgroundVirtual screening: An in silico tool for interlacing the chemical universe with the proteome
Westermaier, Y., Barril, X., & Scapozza, L. (2014) · Methods · doi:10.1016/j.ymeth.2014.08.001 · Cited by 76
Exploring Cryptic Pockets Formation in Targets of Pharmaceutical Interest with SWISH
Comitani, F., & Gervasio, F. L. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00263 · Cited by 72
Genetic-Driven Druggable Target Identification and Validation
Floris, M., Olla, S., Schlessinger, D., & Cucca, F. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.04.004 · Cited by 64
Autism spectrum disorder: prospects for treatment using gene therapy
Benger, M., Kinali, M., & Mazarakis, N. D. (2018) · Molecular Autism · doi:10.1186/s13229-018-0222-8 · Cited by 80
“Many of the encoded proteins implicated in ASD pathogenesis—such as cytoskeletal proteins, cell adhesion molecules and DNA-binding proteins—may be ‘undruggable’ using conventional small molecule drugs, which principally only modulate the function of receptors and enzymes [11].”
BackgroundScreening the receptorome: an efficient approach for drug discovery and target validation
Strachan, R. T., Ferrara, G., & Roth, B. L. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.012 · Cited by 75
Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions
Raj, M., Bullock, B. N., & Arora, P. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.023 · Cited by 66
Enzyme–Inhibitor Interactions and a Simple, Rapid Method for Determining Inhibition Modality
Buker, S. M., Boriack‐Sjodin, P. A., & Copeland, R. A. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219829898 · Cited by 66
Jacobsen, C. J. (2019) · Cambridge University Press eBooks · doi:10.1017/9781139924542 · Cited by 134
Therapeutic prospect of Syk inhibitors
Ruzza, P., Biondi, B., & Calderan, A. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903207039 · Cited by 70
“Consequently, although PKs are encoded by less than 2% of the human genome, they represent more than 20% of the drugable genome, that is, as human genes whose products are likely to represent valuable therapeutic targets [2].”
BackgroundSchistosomiasis: from drug deployment to drug development
Caffrey, C. R., & Secor, W. E. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328349156f · Cited by 71
Neves, B. J., Braga, R. C., Bezerra, J. C. B., Cravo, P., & Andrade, C. H. (2015) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003435 · Cited by 66
“Druggability is related to many factors, including the size of targets, the presence of pockets, and the overall charge and hydrophobicity of the interaction surface [68].”
BackgroundCheminformatics Tools for Analyzing and Designing Optimized Small Molecule Collections and Libraries
Moret, N., Clark, N. A., Hafner, M. A., Wang, Y., Lounkine, E., Medvedovic, M., Wang, J., Gray, N. S., Jenkins, J. L., & Sorger, P. K. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.018 · Cited by 74
“In no cases did a TAS include assertions for all 545 human kinases (Eid et al., 2017), let alone for all ~3000 members of the druggable genome (Hopkins and Groom, 2002), which illustrates the sparseness of target annotation.”
BackgroundOh, M., Lee, J. H., Wang, W., Lee, H. S., Lee, W. S., Burlak, C., Im, W., Hoang, Q. Q., & Lim, H.-S. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320556111 · Cited by 64
“T majority of drugs on the market today target proteins with defined small-molecule binding sites, including enzymes (47%), transmembrane receptors (34%), and transmembrane channels and transporters (11%) (1).”
BackgroundTarget-Pathogen: a structural bioinformatic approach to prioritize drug targets in pathogens
Sosa, E. J., Burguener, G., Lanzarotti, E., Defelipe, L. A., Radusky, L., Pardo, A., Marti, M. A., Turjanski, A. G., & Porto, D. F. D. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1015 · Cited by 72
“Druggability is a concept that describes the ability of a given protein to bind a drug-like compound, which in turn modulates its function in a craved way (8,9).”
BackgroundThe genetic architecture of multimodal human brain age
Wen, J., Zhao, B., Yang, Z., Erus, G., Skampardoni, I., Mamourian, E., Cui, Y., Hwang, G., Bao, J., Boquet-Pujadas, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46796-6 · Cited by 74
Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring
Weil, T., & Renner, S. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci8000265 · Cited by 69
Vamathevan, J. J., Hall, M. D., Hasan, S., Woollard, P. M., Xu, M., Yang, Y., Li, X., Wang, X., Kenny, S., Brown, J. R., et al. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.04.007 · Cited by 65
“We predicted the domains of six major druggable target classes (kinases, proteases, non-olfactory GPCRs, hormone receptors, phosphodiesterases and ligand-gated ion channels) (Hopkins and Groom, 2002) across the gene sets of our nine selected organisms.”
BackgroundMethodThe Presynaptic Component of the Serotonergic System is Required for Clozapine's Efficacy
Yadav, P. N., Abbas, A. I., Farrell, M. S., Setola, V., Sciaky, N., Huang, X., Kroeze, W. K., Crawford, L. K., Piel, D., Keiser, M. J., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.195 · Cited by 66
Cantacessi, C., Jex, A. R., Hall, R. S., Young, N. D., Campbell, B. E., Joachim, A., Nolan, M. J., Abubucker, S., Sternberg, P. W., Ranganathan, S., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq667 · Cited by 72
Hadley, D., Wu, Z.-L., Kao, C., Kini, A., Mohamed-Hadley, A., Thomas, K., Vazquez, L., Qiu, H., Mentch, F., Pellegrino, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5074 · Cited by 62
Efflux pumps and antimicrobial resistance: Paradoxical components in systems genomics
Kabra, R., Chauhan, N., Kumar, A., Ingale, P., & Singh, S. (2018) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2018.07.008 · Cited by 64
“, have been described as a first line of defense against pathogen invasion, including protozoa (Hopkins and Groom, 2002; Lynn et al., 2011; Mangoni et al., 2005; Marr et al., 2016; Toro et al., 2013; Ruiz-Santaquiteria et al., 2017) and are under intense investigation to improve their druggability.”
BackgroundDruggability of the enzymes of the non-mevalonate-pathway
Masini, T., Kroezen, B. S., & Hirsch, A. K. H. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.003 · Cited by 64
Genomic filtering: an approach to discovering novel antiparasitics
McCarter, J. P. (2004) · Trends in Parasitology · doi:10.1016/j.pt.2004.07.008 · Cited by 64
Thansandote, P., Harris, R. M., Dexter, H. L., Simpson, G. L., Pal, S., Upton, R. J., & Valko, K. L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.11.034 · Cited by 69
Host–rabies virus protein–protein interactions as druggable antiviral targets
Lingappa, U. F., Wu, X., Macieik, A., Yu, S. F., Atuegbu, A. E. R., Corpuz, M., Francis, J., Nichols, C., Calayag, A., Hong, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210198110 · Cited by 67
“Effective therapeutic modulation of MPC PPIs would be powerful (25, 26), but a history of unsuccessful attempts has led to the widespread opinion that such targets are not druggable (19).”
BackgroundInfluentialCannabidiol, a novel inverse agonist for GPR12
Brown, K. J., Laun, A. S., & Song, Z.-H. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.001 · Cited by 64
“G protein-coupled receptor 12 (GPR12) belongs to th e rhodopsin families of G protein-coupled receptors (GPCRs), which are import ant therapeutic targets [1, 2].”
Wang, C.-C., Chen, X., Qu, J., Sun, Y., & Li, J. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00129 · Cited by 66
Chasing the Full Free Energy Landscape of Neuroreceptor/Ligand Unbinding by Metadynamics Simulations
Capelli, R., Bochicchio, A. M., Piccini, G., Casasnovas, R., Carloni, P., & Parrinello, M. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b00118 · Cited by 67
Recent Advances in Chemoinformatics
Agrafiotis, D. K., Bandyopadhyay, D., Wegner, J. K., & van Vlijmen, H. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci700059g · Cited by 68
Omasits, U., Québatte, M., Stekhoven, D. J., Fortes, C., Roschitzki, B., Robinson, M. D., Dehio, C., & Ahrens, C. H. (2013) · Genome Research · doi:10.1101/gr.151035.112 · Cited by 66
“…has claimed the identification of a complete proteome expressed in haploid and diploid baker’s yeast (de Godoy et al. 2008), while extensive proteome coverage has been reported for several prokaryotes (Jaffe et al. 2004; Becher et al. 2009; Malmstrom et al. 2009) and archaea (Giannone et al. 2011).”
BackgroundFundamental science behind today’s important medicines
Spector, J., Harrison, R. S., & Fishman, M. C. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1787 · Cited by 67
“Often, the seminal insights into a new drug were made decades before FDA approval and before subsequent stepwise discoveries revealed the target to be “druggable” (3).”
BackgroundG-Protein Coupled Receptors (GPCRs) in Insects—A Potential Target for New Insecticide Development
Liu, N., Li, T., Wang, Y., & Liu, S. (2021) · Molecules · doi:10.3390/molecules26102993 · Cited by 72
Raies, A., Tulodziecka, E., Stainer, J., Middleton, L., Dhindsa, R. S., Hill, P., Engkvist, O., Harper, A. R., Petrovski, S., & Vitsios, D. (2022) · Communications Biology · doi:10.1038/s42003-022-04245-4 · Cited by 61
“…concept in drug discovery that in fl uences target identi fi - cation and may impact the clinical development success concept of the “ druggable genome ” was fi rst introduced in 2002 1 , and was then de fi ned as the ability of a protein to bind a modulator and provide a desired therapeutic effect.”
BackgroundLinker, S. M., Schellhaas, C., Kamenik, A. S., Veldhuizen, M. M., Waibl, F., ROTH, H. ‐., Fouché, M., Rodde, S., & Riniker, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01837 · Cited by 63
Direct and Propagated Effects of Small Molecules on Protein–Protein Interaction Networks
Cesa, L. C., Mapp, A. K., & Gestwicki, J. E. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00119 · Cited by 74
“…targeting the enzymatic components of multi-protein complexes has traditionally been the norm in drug discovery and in chemical biology, it is increasingly appreciated that PPIs could offer several advantages as targets (Hopkins and Groom, 2002; Wells and McClendon, 2007; Gordo and Giralt, 2009).”
BackgroundTetraiodobenzimidazoles are potent inhibitors of protein kinase CK2
Gianoncelli, A., Cozza, G., Orzeszko, A., Meggio, F., Kazimierczuk, Z., & Pinna, L. A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.08.047 · Cited by 63
Elschenbroich, S., Ignatchenko, V., Sharma, P., Schmitt‐Ulms, G., Gramolini, A. O., & Kislinger, T. (2009) · Journal of Proteome Research · doi:10.1021/pr900318k · Cited by 68
To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling
Chew, W. S., Wang, W., & Herr, D. R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.025 · Cited by 67
Multimodal single cell-resolved spatial proteomics reveal pancreatic tumor heterogeneity
Xu, Y., Wang, X., Li, Y., Mao, Y., Su, Y., Mao, Y., Yang, Y., Gao, W., Fu, C., Chen, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54438-0 · Cited by 71
Investigating peptide sequence variations for ‘double-click’ stapled p53 peptides
Lau, Y. H., de Andrade, P., Sköld, N., McKenzie, G. J., Venkitaraman, A. R., Verma, C. S., Lane, D. P., & Spring, D. R. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00742e · Cited by 68
Shevchenko, G., Musunuri, S., Wetterhall, M., & Bergquist, J. (2012) · Journal of Proteome Research · doi:10.1021/pr201169q · Cited by 66
Interaction of Herbal Compounds with Biological Targets: A Case Study with Berberine
Chen, X.-W., Di, Y. M., Zhang, J., Zhou, Z.-W., Li, C. G., & Zhou, S.-F. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/708292 · Cited by 63
“Later, Hopkins and Groom challenged this figure and suggested that “rule-of-five” compliant drugs acted primarily through only 120 underlying molecular targets [3, 7].”
BackgroundProgress and problems in the exploration of therapeutic targets
Zheng, C., Han, L., Yap, C. W., Xie, B., & Chen, Y. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.03.012 · Cited by 62
Holton, T. A., Vijayakumar, V., & Khaldi, N. (2013) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2013.08.009 · Cited by 64
“Indeed, it is estimated that there is approximately 3000 potential drug targets encoded in the human genome alone (Hajduk, Huth, & Tse, 2005; Hopkins & Groom, 2002).”
Rapid High-pH Reverse Phase StageTip for Sensitive Small-Scale Membrane Proteomic Profiling
Dimayacyac-Esleta, B. R. T., Tsai, C., Kitata, R. B., Lin, P.-Y., Choong, W.-K., Lin, T., Wang, Y.-T., Weng, S., Yang, P., Arco, S. D., et al. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03639 · Cited by 64
Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis
Reiche, M., Warner, D. F., & Mizrahi, V. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00075 · Cited by 66
“Importantly, this can also complicate any assessment of the druggability and ligandability of the target protein—both key additional factors in determining the success of the antibiotic development process, and which render gene essentiality alone insufficient for target validation (Hopkins and Groom, 2002; Edfeldt et…”
BackgroundYang, W., Gadgil, P., Krishnamurthy, V. R., Landis, M. S., Mallick, P., Patel, D., Patel, P. J., Reid, D. L., & Sánchez-Félix, M. (2020) · The AAPS Journal · doi:10.1208/s12248-019-0402-2 · Cited by 67
“While biologics such as mAbs, designed to bind to specific target epitopes with high affinity and selectivity, are well-established modalities for extracellular or cell surface targets (1), the non-biologic novel chemical modalities are intended to access and modulate intracellular genomic proteins and contemporary dr…”
Two‐dimensional gel electrophoresis and mass spectrometry for biomarker discovery
Penque, D. (2009) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800025 · Cited by 79
“The biological importance of membrane proteins as well as their being the main targets for most drugs make membrane proteome exploration extremely relevant to the discovery of targets for novel drug design [146].”
Disney, M. D., Dwyer, B. G., & Childs‐Disney, J. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034769 · Cited by 68
Structural Bioinformatics of the Interactome
Petrey, D., & Honig, B. (2014) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-051013-022726 · Cited by 59
“In particular, the considerable robustness of biological networks to the removal of single components, as suggested by experiments in model organisms (68) has prompted a shift away from a traditional “one-disease, one-target” approach (129).”
BackgroundEnabling STD-NMR fragment screening using stabilized native GPCR: A case study of adenosine receptor
Igonet, S., Raingeval, C., Cecon, E., Pučić‐Baković, M., Lauc, G., Cala, O., Baranowski, M., Pérez, J., Jockers, R., Krimm, I., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26113-0 · Cited by 65
G‐protein‐coupled receptor oligomers: two or more for what? Lessons from mGlu and GABAB receptors
Pin, J., Comps‐Agrar, L., Maurel, D., Monnier, C., Rives, M., Trinquet, E., Kniazeff, J., Rondard, P., & Prézeau, L. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.179978 · Cited by 79
“It is then not surprising that these receptors constitute the main target of drugs on the market and still represent the most promising targets for drug development (Hopkins & Groom, 2002; Overington et al. 2006).”
BackgroundHassan, S. S., Tiwari, S., Guimarães, L. C., Jamal, S. B., Folador, E. L., Barve, N., Soares, S. D. C., de Almeida, S. S., Ali, A., Islam, A., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s7-s3 · Cited by 67
“Structural information of target proteins can aid in drug and/or vaccine design and in the discovery of new lead compounds [51].”
BackgroundIsothermal titration calorimetry in membrane protein research
Drączkowski, P., Matosiuk, D., & Jóźwiak, K. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.09.003 · Cited by 63
A Common Protein Fold Topology Shared by Flavonoid Biosynthetic Enzymes and Therapeutic Targets
McArdle, B. M., Campitelli, M. R., & Quinn, R. J. (2005) · Journal of Natural Products · doi:10.1021/np050229y · Cited by 61
Differential recovery of membrane proteins after extraction by aqueous methanol and trifluoroethanol
Zhang, H., Lin, Q., Ponnusamy, S., Kothandaraman, N., Lim, T. K., Zhao, C., Kit, H. S., Arijit, B., Rauff, M., Hew, C., et al. (2007) · PROTEOMICS · doi:10.1002/pmic.200600579 · Cited by 61
Identification of New Genes Involved in Human Adipogenesis and Fat Storage
Söhle, J., Machuy, N., Smailbegovic, E., Holtzmann, U., Grönniger, E., Wenck, H., Stäb, F., & Winnefeld, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031193 · Cited by 73
“For transfection experiments, a siRNA library (SilencerH Human Druggable Genome siRNA Library V3, 384well plates, Ambion, Darmstadt, Germany) containing the druggable human genome [31] with 3 different siRNAs per targeted gene was used.”
MethodWang, W., Guo, T., Rudnick, P. A., Song, T., Li, J., Zhuang, Z., Zheng, W., DeVoe, D. L., Lee, C. S., & Balgley, B. M. (2007) · Analytical Chemistry · doi:10.1021/ac061613i · Cited by 58
Voltage regulates adrenergic receptor function
Rinne, A., Birk, A., & Bünemann, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212656110 · Cited by 61
“This large family of ligand-gated signaling molecules is involved in many physiological and pathophysiological processes, which represent important pharmacological targets (1) and share common downstream signaling pathways (2).”
BackgroundResearch Resource: Nuclear Hormone Receptor Expression in the Endocrine Pancreas
Chuang, J.-C., Cha, J.-Y., Garmey, J. C., Mirmira, R. G., & Joyce J., J. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0568 · Cited by 60
Coordinating the impact of structural genomics on the human α-helical transmembrane proteome
Pieper, U., Schlessinger, A., Kloppmann, E., Chang, G. A., Chou, J. J., Dumont, M. E., Fox, B. G., Fromme, P., Hendrickson, W. A., Malkowski, M. G., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2508 · Cited by 61
Snooker: A Structure-Based Pharmacophore Generation Tool Applied to Class A GPCRs
Sanders, M. P. A., Verhoeven, S., de Graaf, C., Roumen, L., Vroling, B., Nabuurs, S. B., de Vlieg, J., & Klomp, J. P. G. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200088d · Cited by 60
Binding-Site Assessment by Virtual Fragment Screening
Huang, N., & Jacobson, M. P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010109 · Cited by 67
“In this paper we are concerned with protein druggability in the sense defined by Hopkins and Groom [1], i.e., the ability of a protein to bind small, drug-like molecules with high affinity.”
BackgroundInfluentialMcCourt, P., & Desveaux, D. (2009) · New Phytologist · doi:10.1111/j.1469-8137.2009.03045.x · Cited by 71
Oh, S., Jang, H. J., Ko, S. K., Ko, Y., & Park, S. B. (2010) · Journal of Combinatorial Chemistry · doi:10.1021/cc100044w · Cited by 63
Weberpals, J. I., Lo, B., Duciaume, M. M., Spaans, J. N., Clancy, A. A., Dimitroulakos, J., Goss, G. D., & Sekhon, H. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3230 · Cited by 60
“Although direct targeting of HRAS and CTNNB1 regulators of cell division have been unsuccessful as a therapeutic strategy across many tumor types (45), targeting their downstream effectors may be a viable therapeutic alternative.”
BackgroundSusa, A. C., Lippens, J. L., Xia, Z., Loo, J. A., Campuzano, I. D. G., & Williams, E. R. (2017) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-017-1793-x · Cited by 63
“Introduction Membrane proteins currently make up approximately 50% of therapeutic targets [1, 2], making their structural characterization a high priority.”
Kim, J., Bai, Y., Jayne, L. A., Hector, R. D., Persaud, A. K., Ong, S. S., Rojesh, S., Raj, R., Feng, M. J. H. H., Chung, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15638-6 · Cited by 60
Ji, H.-F., Kong, D.-X., Shen, L., Chen, L.-L., Ma, B.-G., & Zhang, H.-Y. (2007) · Genome Biology · doi:10.1186/gb-2007-8-8-r176 · Cited by 59
“Considering the fact that the US Food and Drug Administration (FDA) has approved approximately 2,000 drugs (chemical entities) and there exist only 2,000-3,000 druggable genes and 600-1,500 drug targets [81,82], it is truly possible to find new functions from these old 'safe' drugs, which supports an increasingly shar…”
BackgroundAn overview on enrichment methods for cell surface proteome profiling
Li, Y., Qin, H., & Ye, M. (2019) · Journal of Separation Science · doi:10.1002/jssc.201900700 · Cited by 62
Wang, S., König, G., ROTH, H. ‐., Fouché, M., Rodde, S., & Riniker, S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00775 · Cited by 59
de Boer, R. A., Heymans, S. R. B., Backs, J., Carrier, L., Coats, A. J. S., Dimmeler, S., Eschenhagen, T., Filippatos, G. S., Gepstein, L., Hulot, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2414 · Cited by 62
β-Hairpin protein epitope mimetic technology in drug discovery
Obrecht, D., Chevalier, É., Moehle, K., & Robinson, J. A. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.07.006 · Cited by 59
Effects of Conformational Dynamics on Predicted Protein Druggability
Brown, S. P., & Hajduk, P. J. (2006) · ChemMedChem · doi:10.1002/cmdc.200500013 · Cited by 61
Jongejan, A., Lim, H. D., Smits, R. A., de Esch, I. J. P., Haaksma, E. E. J., & Leurs, R. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci700474a · Cited by 59
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.